Opinion|Videos|February 24, 2025
Assessing Patient Confidence With Biosimilars
Panelists discuss how health care professionals have varying confidence in biosimilars, driven by concerns about efficacy, safety, and interchangeability. Increased education, real-world evidence, professional engagement, transparent regulations, and comprehensive outcome data can help build trust in these alternative biologic treatments.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you view patient confidence with biosimilars so far? What can be done to increase their confidence in biosimilars?
Advertisement
Related to this article
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
Real-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per Cardinal Health review.
Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk stratification.
Advertisement
Advertisement